Preview

Rational Pharmacotherapy in Cardiology

Advanced search

LIS-3 Acute Coronary Syndrome Registry: Changes in Clinical and Demographic Characteristics and Tactics of Prehospital and Hospital Treatment of Surviving Patients After Acute Coronary Syndrome Over a 4-Year Period

https://doi.org/10.20996/1819-6446-2020-04-15

Abstract

Aim. To study the changes in clinical and demographic characteristics, risk factors, treatment tactics, the dynamics of drug therapy at the prehospital stage and prescribed during discharge from the cardiology department over a 4-year period in patients after acute coronary syndrome (ACS) with ST segment elevation and ACS without ST segment elevation.

Material and methods. Data from the LIS-3 prospective registry (Lyubertsy mortality study) was used. Patients admitted to the cardiology department of the Lyubertsy district hospital No. 2 for the first 9 months of 2014 (n=104) and for the first 9 months of 2018 (n=223) with a diagnosis of “ACS with ST segment elevation and ACS without ST segment elevation” and with a confirmed diagnosis at discharge “acute myocardial infarction” (AMI) or “unstable angina” (NSA) were included into the study. Comparison of clinical and demographic indicators, risk factors, the frequency of use of acetylsalicylic acid, clopidogrel, statins, beta-blockers, ACE inhibitors, angiotensin II receptor antagonists, anticoagulants at the prehospital stage and during discharge from the hospital were performed.

Results. Significant differences in the gender and age composition of patients were not found. The number of working patients increased. Compared to 2014, in 2018 the number of patients with arterial hypertension increased (64.4% and 75.8%, respectively, p=0.047), and with coronary heart disease decreased significantly (39.4% and 22.4%, respectively, p=0.004), however, the incidence of atrial fibrillation, history of AMI, and cerebral stroke did not change over the period under consideration. The frequency of concomitant diseases did not practically change, except for kidney diseases, which have become more common. A significant decrease in the frequency of thrombolysis and a significant (more than 6-fold) increase in angioplasty with stenting were found. Patients before ACS in 2014 received less antiplatelet agents than in 2018, including dual antiplatelet therapy, ACE inhibitors were prescribed more often. The intake of nitrates decreased, and the use of statins increased (6.7% versus 13.9%, respectively, p>0.05). AMI as the outcome of ACS was almost the same in both men and women. A downward trend in myocardial Q-infarction (p>0.05) was found. Taking dual antiplatelet therapy and ACE inhibitors were more often recommended at discharge and taking nitrates and any diuretics was less common. Statins intake did not change.

Conclusion. The “portrait” of a hospitalized ACS patient changed somewhat over 4 years: the frequency of the history of coronary heart disease significantly decreased, and the frequency of hypertension increased. The presence and significance of risk factors such as hypercholesterolemia and adverse heredity cannot be assessed as before. The frequency of use of antiplatelet agents and statins increased in prehospital therapy; however, in general, a smaller proportion of patients requiring statins took them. The proportion of AMI patients among ACS ones did not change over the study period.

About the Authors

S. Yu. Martsevich
National Medical Research Center for Therapy and Preventive Medicine
Russian Federation

Sergey Yu. Martsevich – MD, PhD, Professor, Head of Department of Preventive Pharmacotherapy

Petroverigsky per. 10, Moscow, 101990



A. V. Zagrebelnyy
National Medical Research Center for Therapy and Preventive Medicine
Russian Federation

Alexander V. Zagrebelnyy – MD, PhD, Senior Researcher, Department of Preventive Pharmacotherapy

Petroverigsky per. 10, Moscow, 101990



N. P. Zolotareva
National Medical Research Center for Therapy and Preventive Medicine
Russian Federation

Nadezhda P. Zolotareva – MD, Postgraduate Student, Department of Preventive Pharmacotherapy

Petroverigsky per. 10, Moscow, 101990



N. P. Kutishenko
National Medical Research Center for Therapy and Preventive Medicine
Russian Federation

Natalia P. Kutishenko – MD, PhD, Head of Laboratory of Pharmacoepidemiological Research, Department of Preventive Pharmacotherapy

Petroverigsky per. 10, Moscow, 101990



Yu. V. Lukina
National Medical Research Center for Therapy and Preventive Medicine
Russian Federation

Yulia V. Lukina – MD, PhD, Leading Researcher, Laboratory of Pharmacoepidemiological Research, Department of Preventive Pharmacotherapy

Petroverigsky per. 10, Moscow, 101990



M. L. Ginzburg
Lyubertsy Regional Hospital
Russian Federation

Moisey L. Ginzburg – MD, Head of Cardiology Department for Treatment of Patients with Acute Coronary Syndrome

Octyabrskiy prospect 338, Lyubertsy, Moscow Region, 140006



D. A. Startsev
Lyubertsy Regional Hospital
Russian Federation

Dmitry A. Startsev – MD, Chief Physician

Octyabrskiy prospect 338, Lyubertsy, Moscow Region, 140006



S. V. Blagodatskikh
National Medical Research Center for Therapy and Preventive Medicine
Russian Federation

Svetlana V. Blagodatskikh – PhD (Chemistry), Senior Researcher, Department of Preventive Pharmacotherapy

Petroverigsky per. 10, Moscow, 101990



References

1. Go A.S., Mozaffarian D., Roger V.L., et al. Heart disease and stroke statistics - 2014 update: a report from the American Heart Association. Circulation. 2014;129(3):e28-e292. DOI:10.1161/01.cir.0000441139.02102.80.

2. Marcevich S.Y., Ginzburg M.L., Kutishenko N.P., et al. The LIS study (Lyubertsy study of mortality in patients with acute myocardial infarction). Evaluation of the pharmacotherapy. Part 1. Treatment of patients before myocardial infarction and its influence on hospital mortality rate. Rational Pharmacotherapy in Cardiology. 2012;8(5):681-4 (In Russ). DOI:10.20996/1819-6446-2012-8-5-681-68.

3. Martsevich S.Y., Gynzburg M.L., Kutishenko N.P., et al. The LIS study (Lyubertsy study on mortality rate in patients after acute myocardial infarction). Evaluation of drug therapy. Part 2. Influence of previous drug treatment on long-term life prognosis. Rational Pharmacotherapy in Cardiology. 2012;8:738-45 (In Russ.). DOI: 10.20996/1819-6446-2012-8-6-738-745.

4. Lukina Yu.V., Ginzburg M.L., Smirnov V.P., et al. Treatment compliance, in patiens with acute coronary syndrom before hospitalization. The Clinician. 2012;2:41-9 (In Russ). DOI:10.17650/1818-8338-2012-6-2-41-49.

5. Martsevich S.Y., Semenova Y.V., Kutishenko N.P., et al. Assessment of patients attendance at outpatient clinics and prehospital therapy: Russian acute coronary syndrome registry LISS-3 data. Indian Heart J. 2017;69:105-6. DOI:10.1016/j.ihj.2016.11.005.

6. Martsevich S.Y., Ginzburg M.L., Kutishenko N.P., et al. Lyubertsy mortality study (LMS): factors influencing the long-term survival after myocardial infarction. Profilakticheskaya Meditsina. 2013;16(2):32-8 (In Russ).

7. Semenova Yu.V., Kutishenko N.P., Zagebelnyy A.V., et al. Influence of Patients’ Prehospital Attendance at Outpatient Clinics on Long-Term Outcomes of Acute Coronary Syndrome: LIS-3 Study. Rational Pharmacotherapy in Cardiology. 2017;13(3):363-9 (In Russ.). DOI:10.20996/1819-6446-2017-13-3-363-369.

8. Martsevich S.Yu., Ginsburg M.L., Kutishenko N.P., et al. LIS Study (Lyubertsy Study of mortality in patients after acute myocardial infarction): the patients' portrait. Cardiovascular Therapy and Prevention. 2011;10(6):89-93 (In Russ).

9. Martsevich S.Y., Semenova Y.V., Kutishenko N.P., et al. Awareness of cardiovascular disease, its risk factors, and its association with attendance at outpatient clinics in acute coronary syndrome patients. Integrative Medicine Research. 2017;6(3):240-4. DOI:10.1016/j.imr.2017.06.003.

10. Martsevich S.Y., Ginzburg M.L., Kutishenko N.P., et al. A Lyubertsy study of mortality among patients with prior acute myocardial infarction: the first results of the LIS study. The Clinician. 2011;1;24-8 (In Russ).

11. LaBounty, T., Gurm H.S., Goodman S. G., et al. Predictors and implications of Q-waves in STelevation acute coronary syndromes. Am J Med. 2009;122(2):144-51. DOI:10.1016/j.amjmed.2008.08.029.

12. Lee H.Y., Cooke C.E., Robertson T.A. Use of secondary prevention drug therapy in patients with acute coronary syndrome after hospital discharge. J Manag Care Pharm. 2008;14(3):271-80. DOI:10.18553/jmcp.2008.14.3.271.

13. Lukina Y.V., Kutishenko N.P., Martsevich S.Y. The Problem of Adherence to the Treatment in Modern Medicine: Possibilities of Solution, Impact on the Effectiveness of Therapy and Disease Outcomes. Rational Pharmacotherapy in Cardiology. 2017;13(4):519-524 (In Russ.). DOI:10.20996/1819-6446-2017-13-4-519-524.


Review

For citations:


Martsevich S.Yu., Zagrebelnyy A.V., Zolotareva N.P., Kutishenko N.P., Lukina Yu.V., Ginzburg M.L., Startsev D.A., Blagodatskikh S.V. LIS-3 Acute Coronary Syndrome Registry: Changes in Clinical and Demographic Characteristics and Tactics of Prehospital and Hospital Treatment of Surviving Patients After Acute Coronary Syndrome Over a 4-Year Period. Rational Pharmacotherapy in Cardiology. 2020;16(2):266-272. (In Russ.) https://doi.org/10.20996/1819-6446-2020-04-15

Views: 487


Creative Commons License
This work is licensed under a Creative Commons Attribution 4.0 License.


ISSN 1819-6446 (Print)
ISSN 2225-3653 (Online)